Reduced expression of NLRP3 has been observed in JSpA and it is proposed that this contributes to permeability of the gut and subclinical inflammation which is seen in studies with defective NLRP3 inflammasome signaling (i.e., inflammatory bowel disease) [98,99]. The gene discussed is NLRP3; the disease is inflammatory bowel disease.